With the S&P/ASX 200 down as much as 130 points on Wednesday morning and a large percentage of Monday’s substantial rebound now lost, it may pay to scour the market for pockets of value.

While also succumbing to the downturn in the broader market, the healthcare sector has substantially outperformed the XJO over the last three months, and in fact it is in positive territory to the tune of about 5%.

By comparison, the XJO is down 22%.

Though large cap Biotechs on the ASX such as CSL, ResMed and Ramsay Health Care have underpinned the strong performance, there are stocks worth targeting outside the blue chips.

One such stock is AVITA Medical Limited (ASX:AVH), a market darling from fiscal 2019, a period in which its share price increased by about 500% from 7.1 cents on July 1, 2018 to 42 cents on June 30, 2019.

However, there was more to come as the company’s shares doubled again in the eight months to February 2020, hitting an all-time high of 86.5 cents just before the market crashed.

Despite the company not delivering any negative news, its share price plummeted, trading below 40 cents in mid-March.

While Avita has recovered to some extent in the last fortnight, there still appears to be scope for upside, particularly in light of a positive trading update provided by management on Monday.

Technology has multiple applications

To provide some background, AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications.

AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin.

The medical devices work by preparing a REGENERATIVE EPIDERMAL SUSPENSION (RES®), an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis.

This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical’s first US product, the RECELL® System, was approved by the US Food and Drug Administration (FDA) in September 2018.

Compelling data from randomised, controlled clinical trials conducted at major US burn centres and real-world use in more than 8,000 patients globally, reinforces that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings.

This is backed up by the company’s strong sales growth which has continued into 2020.

March quarter revenue of $6 million represented a 21% increase compared with the December quarter and US RECELL sales were up 22%.

Quarter on quarter procedural volumes increased by 23%, and ongoing demand should be supported by the general categorisation of burn treatments as ‘non-elective’.

Providing investors with further confidence in the company’s ability to face any headwinds that do occur, the group had cash of $130 million as at March 31, 2020.

Setting aside COVID-19, this also leaves the company well-positioned to progress its research and development, as well as commercial distribution of its existing technologies.